HUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting

Stock News

Nov 27, 2025

HUTCHMED (00013) announced that updated and latest data from several studies of its self-developed compounds will be presented at two major medical conferences in December 2025. The European Society for Medical Oncology (ESMO) Asia Congress will be held in Singapore from December 5-7, 2025, while the American Society of Hematology (ASH) Annual Meeting will take place in Orlando, USA, from December 6-9, 2025.

At the ESMO Asia Congress, HUTCHMED will disclose the first-in-human clinical trial results of its anti-CD47 monoclonal antibody HMPL-A83 for treating advanced solid tumors. Additionally, the company will present Phase II results from the FRUSICA-2 registration study evaluating fruquintinib combined with sintilimab as a second-line treatment for locally advanced or metastatic renal cell carcinoma.

The conference will also feature Phase II results from a separate study investigating surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1115731169"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115731169\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115731169?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115731169","market":"sh","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting","media":"Stock News","content":"<p>HUTCHMED (00013) announced that updated and latest data from several studies of its self-developed compounds will be presented at two major medical conferences in December 2025. The European Society for Medical Oncology (ESMO) Asia Congress will be held in Singapore from December 5-7, 2025, while the American Society of Hematology (ASH) Annual Meeting will take place in Orlando, USA, from December 6-9, 2025.</p>\n<p>At the ESMO Asia Congress, HUTCHMED will disclose the first-in-human clinical trial results of its anti-CD47 monoclonal antibody HMPL-A83 for treating advanced solid tumors. Additionally, the company will present Phase II results from the FRUSICA-2 registration study evaluating fruquintinib combined with sintilimab as a second-line treatment for locally advanced or metastatic renal cell carcinoma.</p>\n<p>The conference will also feature Phase II results from a separate study investigating surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) announced that updated and latest data from several studies of its self-developed compounds will be presented at two major medical conferences in December 2025. The European Society for Medical Oncology (ESMO) Asia Congress will be held in Singapore from December 5-7, 2025, while the American Society of Hematology (ASH) Annual Meeting will take place in Orlando, USA, from December 6-9, 2025.</p>\n<p>At the ESMO Asia Congress, HUTCHMED will disclose the first-in-human clinical trial results of its anti-CD47 monoclonal antibody HMPL-A83 for treating advanced solid tumors. Additionally, the company will present Phase II results from the FRUSICA-2 registration study evaluating fruquintinib combined with sintilimab as a second-line treatment for locally advanced or metastatic renal cell carcinoma.</p>\n<p>The conference will also feature Phase II results from a separate study investigating surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4531","symbol_name":"中概回港概念","start_time":0,"source_url":"","article_id":"1115731169","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115731169","pubTimestamp":1764202097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that updated and latest data from several studies of its self-developed compounds will be presented at two major medical conferences in December 2025. The European Society...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4531":"中概回港概念","BK4588":"碎股","BK1191":"制药","00013":"和黄医药","BK1588":"回港中概股","BK4585":"ETF&股票定投概念","BK1587":"次新股","HCM":"和黄医药","ASH":"Ashland","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK4109":"特种化学制品","BK4007":"制药"},"translate_title":"和黄医药(00013)将于2025年ESMO亚洲大会暨ASH年会展示临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASH":1,"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced that updated and latest data from several studies of its self-developed compounds will be presented at two major medical conferences in December 2025. The European Society for Medical Oncology (ESMO) Asia Congress will be held in Singapore from December 5-7, 2025, while the American Society of Hematology (ASH) Annual Meeting will take place in Orlando, USA, from December 6-9, 2025.\nAt the ESMO Asia Congress, HUTCHMED will disclose the first-in-human clinical trial results of its anti-CD47 monoclonal antibody HMPL-A83 for treating advanced solid tumors. Additionally, the company will present Phase II results from the FRUSICA-2 registration study evaluating fruquintinib combined with sintilimab as a second-line treatment for locally advanced or metastatic renal cell carcinoma.\nThe conference will also feature Phase II results from a separate study investigating surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}